Combined modality therapy of solid tumours

Lancet

Volumn 349, Issue SUPPL.2, 1997, Pages

  Vokes, Everett E ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; MITOMYCIN; TAMOXIFEN; VINBLASTINE;

CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; HUMAN; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; SHORT SURVEY; SOLID TUMOR; TREATMENT OUTCOME;

EID: 0031009248     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(97)90011-8     Document Type: Article

References (27)

1. DeVita VT Jr. Principles of cancer management: chemotherapy. In: Devita VT Jr, Hellman S, Rosenberg SA, eds. Principles and practice of oncology. 5th ed. Philadelphia: Lippincott, 1997: 333-48.
2. Vokes EE, Weichselbaum RR. Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol 1990, 8: 911-34.
3. Tannock IF. Treatment of cancer with radiation and drugs. J Clin Oncol 1996; 14: 3156-74.
4. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685-90.
5. Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial: EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996; 88: 855-66.
6. Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, Efird JT. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 1993; 329: 1377-82.
7. Harris JR, Lippman ME, Veronesi U, Willett W. Breast cancer: medical progress. N Engl J Med 1992; 327: 319-28.
8. Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1995; 333: 1456-61.
9. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 341 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 339: 1-15, 71-84.
10. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. N Engl J Med 1995; 332: 901-6.
11. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996; 348: 1189-96.
12. Dhingra K, Hortobagyi GN. Critical evaluation of prognostic factors. Semin Oncol 1996; 23: 436-45.
13. Silvestrini R, Daidone MG, Luisi A, et al. Biologic and clinicopathologic factors as indicators of specific relapse types in node negative breast cancer. J Clin Oncol 1995; 3: 697-704.
14. Muss HB, Thor AD, Berry DA, et al. c-erb-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260-66.
15. Peters WP. High-dose chemotherapy and autologous bone marrow support for breast cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Important advances in oncology. Philadelphia: Lippincott, 1991: 135-50.
16. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994; 330:1136-42.
17. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122: 321-26.
18. O'Connell MJ, Martenson JA, Wieand HS, Krook JE, MacDonald JS, Haller DG. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy with curative surgery. N Engl J Med 1994; 331: 502-27.
19. Malawer MM, Link MP, Donaldson SS. Sarcomas of bone. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer principles and practice of oncology. 4th ed. Philadelphia: Lippincott, 1993: 1509-66.
20. Ginsberg R, Yokes EE, Raben A. Non-small cell lung cancer. In: DeVita Jr VT, Hellman S, Rosenberg SA, eds. Cancer - principles and practice of oncology. 5th ed. Philadelphia: Lippincott, 1997: 858-910.
21. Dillman RO, Herndon J, Seagren SL, Eaton WL, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B 8433 Trial. J Natl Cancer Inst 1996; 88: 1210-15.
22. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995; 87: 198-205.
23. Yokes EE, Weichselbaum RR, Lippman S, Hong WK. Head and neck cancer. N Engl J Med 1993; 328: 184-94.
24. Sternberg CN. Neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer. Semin Oncol 1996; 23: 621-32.
25. Flam MS, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive non-surgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996; 14: 2527-39.
26. Al-Sarraf M, Martz K, Herskovic A, et al. Superiority of chemoradiotherapy (CT-RT) vs radiotherapy (RT) in patients with esophageal cancer: final report of an intergroup randomized and confirmed study. Proc Am Soc Clin Oncol 1996; 15: 206 (abstr).
27. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: 462-510.